Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Heather, Beckwith"'
Autor:
Adnan Shaaban, Ashley Petersen, Heather Beckwith, Natalia Florea, David A. Potter, Douglas Yee, Rachel I. Vogel, Daniel Duprez, Anne H. Blaes
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-6 (2024)
Abstract Background Breast cancer is estimated to comprise about 290,560 new cases in 2022. Aromatase inhibitors (AIs) are recommended as adjuvant treatment for estrogen-receptor positive (ER+) breast carcinoma in postmenopausal women, which includes
Externí odkaz:
https://doaj.org/article/917744b9547c414697dfbb20c72e3268
Autor:
Julie E. Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A. Parker, A. Jo Chien, Anne M. Wallace, Rashmi Murthy, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Rachel L. Yung, Claudine Isaacs, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Erica Stringer-Reasor, Elissa Price, Bonnie Joe, Minetta C. Liu, Lamorna Brown-Swigart, Emanuel F. Petricoin, Julia D. Wulfkuhle, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van ‘t Veer, Nola M. Hylton, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in
Externí odkaz:
https://doaj.org/article/f1ec1969e2aa401dafdcc1102c26a20e
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8
Autor:
Mark Jesus M. Magbanua, Laura van ‘t Veer, Amy S. Clark, A. Jo Chien, Judy C. Boughey, Hyo S. Han, Anne Wallace, Heather Beckwith, Minetta C. Liu, Christina Yau, E. Paul Wileyto, Andrea Ordonez, Tulasi I. Solanki, Feng Hsiao, Jen Chieh Lee, Amrita Basu, Lamorna Brown Swigart, Jane Perlmutter, Amy L. Delson, Lauren Bayne, Shannon Deluca, Stephanie S. Yee, Erica L. Carpenter, Laura J. Esserman, John W. Park, Lewis A. Chodosh, Angela DeMichele
Publikováno v:
Breast Cancer Research and Treatment. 198:383-390
Autor:
Lauren Thomaier, Deanna Teoh, Patricia Jewett, Heather Beckwith, Helen Parsons, Jianling Yuan, Anne H Blaes, Emil Lou, Jane Yuet Ching Hui, Rachel I Vogel
Publikováno v:
PLoS ONE, Vol 15, Iss 11, p e0242767 (2020)
IntroductionCancer care is significantly impacted by the Coronavirus Disease 2019 (COVID-19) pandemic. Our objective was to evaluate the early effects of the pandemic on the emotional well-being of oncology providers across the United States and expl
Externí odkaz:
https://doaj.org/article/1555feb57e4840469eff9414ffb7a0c9
Autor:
Haiyun Wang, Douglas Yee, David Potter, Patricia Jewett, Christina Yau, Heather Beckwith, Allison Watson, Nicholas O'Grady, Amy Wilson, Susie Brain, Paula Pohlmann, Anne Blaes
Purpose Increased body mass index (BMI) has been associated with poor outcomes in women with breast cancer. We evaluated the association between BMI and pathological complete response (pCR) in the I-SPY 2 trial. Methods 978 patientsenrolled in the I-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f36c81208397b35f80eb6c17f167f45b
https://doi.org/10.21203/rs.3.rs-2588168/v1
https://doi.org/10.21203/rs.3.rs-2588168/v1
Autor:
Adnan Shaaban, Ashley Petersen, Heather Beckwith, Natalia Florea, David A. Potter, Douglas Yee, Rachel I. Vogel, Daniel Duprez, Anne H. Blaes
Background Aromatase inhibitors (AIs) are recommended as adjuvant treatment for estrogen-receptor positive breast carcinoma in postmenopausal women. Studies demonstrate mixed results as to the impact of AIs on cardiovascular (CV) events and overall s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::babb7c3a48bb2e0a370cc96159e7f3e4
https://doi.org/10.21203/rs.3.rs-2758909/v1
https://doi.org/10.21203/rs.3.rs-2758909/v1
Autor:
Todd M Tuttle, David Potter, Jane Yuet Ching Hui, Schelomo Marmor, J. Asher Jenkins, Anne H. Blaes, Heather Beckwith
Publikováno v:
Breast Cancer Research and Treatment. 191:401-407
Genomic expression assays provide prognostic information and guide adjuvant chemotherapy decisions for patients with estrogen receptor (ER)-positive breast cancer. Few studies have evaluated the utility of such assays for invasive lobular carcinoma (
Autor:
Laura van 't Veer, E. Paul Wileyto, Erica L. Carpenter, Judy C. Boughey, Lamorna Brown Swigart, Mark Jesus M. Magbanua, Amy S. Clark, Stephanie S. Yee, Heather Beckwith, A. Jo Chien, Angela DeMichele, Christina Yau, John W. Park, Jane Perlmutter, Anne M. Wallace, Lewis A. Chodosh, HS Han, Lauren J. Bayne, Shannon DeLuca, Laura J. Esserman, Minetta C. Liu
Publikováno v:
Cancer Research. 81:PS2-07
Background: Disseminated tumor cells (DTCs) in bone marrow detected after treatment may represent occult residual disease. We enumerated DTCs after neoadjuvant chemotherapy (NACT) in patients (pts) diagnosed with high-risk early stage breast cancer a
Autor:
HS Han, Christina Yau, Jane Perlmutter, Amy Wilson, Heather Beckwith, Anne M. Wallace, Tara Sanft, Ashish Sanil, Erica Stringer-Reasor, Laura J. Esserman, Zahi Mitri, Donald A. Berry, Rita Nanda, Claudine Isaacs, Alexandra Thomas, Kevin Kalinsky, Hope S. Rugo, Michelle E. Melisko, A. Jo Chien, Smita Asare, W. Fraser Symmans, Judy C. Boughey, Douglas Yee, Laura J. van't Veer, Kathy S. Albain, Amy S. Clark, Julie E. Lang, Anthony D. Elias, Nola M. Hylton, Angela DeMichele, Shi Wei, Richard Schwab
Publikováno v:
Cancer Research. 81:PD1-10
Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint (MP) risk to evaluate novel agents as neoadjuvant therapy for women with high-risk stage II/